Patients with lower EGC-Alb had a higher risk of adverse events, such as all-cause mortality, new-onset hypoalbuminemia, new-onset CKD, new-onset hepatitis, CVD mortality, new-onset AMI, new-onset STK, new-onset CAD, new-onset HF, and new-onset Afib. This evidence concerns the gene ALB and Hepatitis.